



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Ozoralizumab

Cat. No.:	HY-P99796
CAS No.:	1167985-17-2
Target:	TNF Receptor
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ozoralizumab (ATN-103) is an anti-TNF α humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNF α nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis ^[1] .								
In Vitro	Ozoralizumab (ATN-103; 0-1000 pM; 48 h) has high TNF α -neutralizing potency in the L929 cell cytotoxicity assay with K _D values of 20.2 pM and 16.1 pM for human TNF α and monkey TNF α , respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	Ozoralizumab (ATN-103; 1 mg/kg; s.c.; Tg197 human TNF transgenic mice) inhibits arthritis and reduces arthritis scores ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table> <tr> <td>Animal Model:</td> <td>Tg197 human TNF transgenic mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Subcutaneous injection</td> </tr> <tr> <td>Result:</td> <td>Reduced the mean histopathologic score in the Tg197 mice. Had ability to neutralize TNFα activity.</td> </tr> </table>	Animal Model:	Tg197 human TNF transgenic mice ^[1]	Dosage:	1 mg/kg	Administration:	Subcutaneous injection	Result:	Reduced the mean histopathologic score in the Tg197 mice. Had ability to neutralize TNF α activity.
Animal Model:	Tg197 human TNF transgenic mice ^[1]								
Dosage:	1 mg/kg								
Administration:	Subcutaneous injection								
Result:	Reduced the mean histopathologic score in the Tg197 mice. Had ability to neutralize TNF α activity.								

REFERENCES

[1]. Ishiwatari-Ogata C, et, al. Ozoralizumab, a Humanized Anti-TNF α NANOBODY® Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNF α IgG. Front Immunol. 2022 Feb 22;13:853008.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA